dehydroepiandrosterone has been researched along with Disease Exacerbation in 19 studies
Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.
dehydroepiandrosterone : An androstanoid that is androst-5-ene substituted by a beta-hydroxy group at position 3 and an oxo group at position 17. It is a naturally occurring steroid hormone produced by the adrenal glands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "DHEA treatment did not alter disease progression or survival in SOD1-G93A rats." | 5.38 | Gonadectomy and dehydroepiandrosterone (DHEA) do not modulate disease progression in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis. ( Hayes-Punzo, A; McHugh, J; Meyer, M; Mulcrone, P; Suzuki, M; Svendsen, CN, 2012) |
| "Depression was assessed using Beck Depression Inventory (BDI) and defined as BDI > or =16 points." | 5.36 | Deficiencies in circulating testosterone and dehydroepiandrosterone sulphate, and depression in men with systolic chronic heart failure. ( Banasiak, W; Borodulin-Nadzieja, L; Drohomirecka, A; Jankowska, EA; Lopuszanska, M; Ponikowska, B; Ponikowski, P; Poole-Wilson, PA; Szklarska, A; Witkowska, A, 2010) |
| "Androgen blockade-naïve prostate cancer (PCa) develops into CRPC during androgen deprivation therapy (ADT) by various genetic actions." | 2.52 | Reconsideration of progression to CRPC during androgen deprivation therapy. ( Mizokami, A; Namiki, M, 2015) |
| "DHEA treatment did not alter disease progression or survival in SOD1-G93A rats." | 1.38 | Gonadectomy and dehydroepiandrosterone (DHEA) do not modulate disease progression in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis. ( Hayes-Punzo, A; McHugh, J; Meyer, M; Mulcrone, P; Suzuki, M; Svendsen, CN, 2012) |
| "Depression was assessed using Beck Depression Inventory (BDI) and defined as BDI > or =16 points." | 1.36 | Deficiencies in circulating testosterone and dehydroepiandrosterone sulphate, and depression in men with systolic chronic heart failure. ( Banasiak, W; Borodulin-Nadzieja, L; Drohomirecka, A; Jankowska, EA; Lopuszanska, M; Ponikowska, B; Ponikowski, P; Poole-Wilson, PA; Szklarska, A; Witkowska, A, 2010) |
| "In rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), patients demonstrate low levels of adrenal hormones." | 1.32 | Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus. ( Demmel, B; Herrmann, M; Kees, F; Schedel, J; Schmidt, M; Schölmerich, J; Straub, RH; Weidler, C, 2004) |
| " However, a dose-response reduction in invasive carcinoma growth was observed for both DFMO, an inhibitor of ornithine decarboxylase, and DHEA, the primary steroid precursor to both androgens and estrogens in primates." | 1.31 | 2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. ( Anver, MR; Green, JE; Kelloff, G; Lubet, R; Moon, RC; Shibata, E; Shibata, MA, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 10 (52.63) | 29.6817 |
| 2010's | 8 (42.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Rochette, E | 1 |
| Merlin, E | 1 |
| Hourdé, C | 1 |
| Evrard, B | 1 |
| Peraira, B | 1 |
| Echaubard, S | 1 |
| Duché, P | 1 |
| Pietri, E | 1 |
| Massa, I | 1 |
| Bravaccini, S | 1 |
| Ravaioli, S | 1 |
| Tumedei, MM | 1 |
| Petracci, E | 1 |
| Donati, C | 1 |
| Schirone, A | 1 |
| Piacentini, F | 1 |
| Gianni, L | 1 |
| Nicolini, M | 1 |
| Campadelli, E | 1 |
| Gennari, A | 1 |
| Saba, A | 1 |
| Campi, B | 1 |
| Valmorri, L | 1 |
| Andreis, D | 1 |
| Fabbri, F | 1 |
| Amadori, D | 1 |
| Rocca, A | 1 |
| Audenet, F | 1 |
| Murez, T | 1 |
| Ripert, T | 1 |
| Villers, A | 1 |
| Neuzillet, Y | 1 |
| Mizokami, A | 1 |
| Namiki, M | 1 |
| Huang, K | 1 |
| Bao, JP | 1 |
| Jennings, GJ | 1 |
| Wu, LD | 1 |
| Manco, M | 1 |
| Bottazzo, G | 1 |
| Auci, DL | 1 |
| Mangano, K | 1 |
| Destiche, D | 1 |
| White, SK | 1 |
| Huang, Y | 1 |
| Boyle, D | 1 |
| Frincke, J | 1 |
| Reading, CL | 1 |
| Nicoletti, F | 1 |
| Jankowska, EA | 1 |
| Drohomirecka, A | 1 |
| Ponikowska, B | 1 |
| Witkowska, A | 1 |
| Lopuszanska, M | 1 |
| Szklarska, A | 1 |
| Borodulin-Nadzieja, L | 1 |
| Banasiak, W | 1 |
| Poole-Wilson, PA | 1 |
| Ponikowski, P | 1 |
| Hayes-Punzo, A | 1 |
| Mulcrone, P | 1 |
| Meyer, M | 1 |
| McHugh, J | 1 |
| Svendsen, CN | 1 |
| Suzuki, M | 1 |
| Christeff, N | 1 |
| De Truchis, P | 1 |
| Melchior, JC | 1 |
| Perronne, C | 1 |
| Gougeon, ML | 1 |
| Straub, RH | 1 |
| Weidler, C | 1 |
| Demmel, B | 1 |
| Herrmann, M | 1 |
| Kees, F | 1 |
| Schmidt, M | 1 |
| Schölmerich, J | 1 |
| Schedel, J | 1 |
| Ramsaransing, GS | 1 |
| Heersema, DJ | 1 |
| De Keyser, J | 1 |
| Marx, CE | 1 |
| Trost, WT | 1 |
| Shampine, LJ | 1 |
| Stevens, RD | 1 |
| Hulette, CM | 1 |
| Steffens, DC | 1 |
| Ervin, JF | 1 |
| Butterfield, MI | 1 |
| Blazer, DG | 1 |
| Massing, MW | 1 |
| Lieberman, JA | 1 |
| Brind, J | 1 |
| van Vollenhoven, RF | 1 |
| Scott, A | 1 |
| Higdon, K | 1 |
| Tucci, M | 1 |
| Benghuzzi, H | 1 |
| Puckett, A | 1 |
| Tsao, A | 1 |
| Cason, Z | 1 |
| Hughes, J | 1 |
| Green, JE | 1 |
| Shibata, MA | 1 |
| Shibata, E | 1 |
| Moon, RC | 1 |
| Anver, MR | 1 |
| Kelloff, G | 1 |
| Lubet, R | 1 |
| Piketty, C | 1 |
| Jayle, D | 1 |
| Gonzalez-Canali, G | 1 |
| Debuire, B | 1 |
| Baulieu, EE | 1 |
| Kazatchkine, MD | 1 |
| Masera, RG | 1 |
| Prolo, P | 1 |
| Sartori, ML | 1 |
| Staurenghi, A | 1 |
| Griot, G | 1 |
| Ravizza, L | 1 |
| Dovio, A | 1 |
| Chiappelli, F | 1 |
| Angeli, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Non Randomized Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT)[NCT02000375] | Phase 2 | 20 participants (Actual) | Interventional | 2013-03-31 | Terminated (stopped due to Due to slow recruitment and recent new published data) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for dehydroepiandrosterone and Disease Exacerbation
| Article | Year |
|---|---|
[CYP17A1 inhibitors in prostate cancer: mechanisms of action independent of the androgenic pathway].
Topics: Abiraterone Acetate; Adjuvants, Immunologic; Androgens; Androstadienes; Androstenedione; Antineoplas | 2013 |
Reconsideration of progression to CRPC during androgen deprivation therapy.
Topics: Androgen Antagonists; Androgens; Dehydroepiandrosterone; Disease Progression; Docetaxel; Humans; Mal | 2015 |
Dehydroepiandrosterone in systemic lupus erythematosus.
Topics: Adjuvants, Immunologic; Animals; Clinical Trials as Topic; Dehydroepiandrosterone; Disease Models, A | 2000 |
1 trial available for dehydroepiandrosterone and Disease Exacerbation
| Article | Year |
|---|---|
Phase II Study of Dehydroepiandrosterone in Androgen Receptor-Positive Metastatic Breast Cancer.
Topics: Administration, Oral; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aroma | 2019 |
15 other studies available for dehydroepiandrosterone and Disease Exacerbation
| Article | Year |
|---|---|
Inflammatory Response 24 h Post-Exercise in Youth with Juvenile Idiopathic Arthritis.
Topics: Adolescent; Adrenocorticotropic Hormone; Arthritis, Juvenile; Biomarkers; Child; Cytokine Receptor g | 2018 |
The disease-modifying effect of dehydroepiandrosterone in different stages of experimentally induced osteoarthritis: a histomorphometric study.
Topics: Animals; Antirheumatic Agents; Dehydroepiandrosterone; Disease Models, Animal; Disease Progression; | 2015 |
Does the hormone of eternal youth protect against nonalcoholic steatohepatitis?
Topics: Adiponectin; Dehydroepiandrosterone; Disease Progression; Fatty Acids, Nonesterified; Fatty Liver; H | 2008 |
Oral treatment with HE3286 ameliorates disease in rodent models of rheumatoid arthritis.
Topics: Administration, Oral; Animals; Arthritis, Experimental; Arthritis, Rheumatoid; Body Weight; Dehydroe | 2010 |
Deficiencies in circulating testosterone and dehydroepiandrosterone sulphate, and depression in men with systolic chronic heart failure.
Topics: Adult; Biomarkers; Dehydroepiandrosterone; Depression; Disease Progression; Follow-Up Studies; Heart | 2010 |
Gonadectomy and dehydroepiandrosterone (DHEA) do not modulate disease progression in the G93A mutant SOD1 rat model of amyotrophic lateral sclerosis.
Topics: Amyotrophic Lateral Sclerosis; Animals; Animals, Genetically Modified; Dehydroepiandrosterone; Disea | 2012 |
Longitudinal evolution of HIV-1-associated lipodystrophy is correlated to serum cortisol:DHEA ratio and IFN-alpha.
Topics: Adult; Antiretroviral Therapy, Highly Active; Apolipoprotein A-I; Apolipoproteins B; Cholesterol; Ch | 2002 |
Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus.
Topics: 17-alpha-Hydroxyprogesterone; Adrenal Cortex Hormones; Adult; Androstenedione; Arthritis, Rheumatoid | 2004 |
Serum uric acid, dehydroepiandrosterone sulphate, and apolipoprotein E genotype in benign vs. progressive multiple sclerosis.
Topics: Adult; Apolipoproteins E; Dehydroepiandrosterone; Disease Progression; Female; Genotype; Humans; Mal | 2005 |
The neurosteroid allopregnanolone is reduced in prefrontal cortex in Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Biomarkers; Chromatography, High Pressure Liquid; Dehydroepiandrosterone; D | 2006 |
Spotlight on DHEA: a marker for progression of HIV infection?
Topics: Acquired Immunodeficiency Syndrome; Biomarkers; CD4 Lymphocyte Count; Dehydroepiandrosterone; Diseas | 1996 |
The prevention of osteoporotic progression by means of steroid loaded TCPL drug delivery systems.
Topics: Animals; Bone Resorption; Calcium Phosphates; Dehydroepiandrosterone; Diosgenin; Disease Progression | 2001 |
2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice.
Topics: Animals; Anticarcinogenic Agents; Antigens, Polyomavirus Transforming; Apoptosis; Cell Division; Deh | 2001 |
Low plasma levels of dehydroepiandrosterone (DHEA) and incidence of lipodystrophy.
Topics: Adult; Antiretroviral Therapy, Highly Active; Biological Availability; Dehydroepiandrosterone; Dehyd | 2001 |
Mental deterioration correlates with response of natural killer (NK) cell activity to physiological modifiers in patients with short history of Alzheimer's disease.
Topics: Aged; Alzheimer Disease; Cytokines; Cytotoxicity, Immunologic; Dehydroepiandrosterone; Disease Progr | 2002 |